Results 1 to 10 of about 11,222 (94)

Do PCSK9 Inhibitors Impair Memory? A Dual Approach Combining Real-World Data and Genetic Evidence [PDF]

Pharmacy
Emerging evidence suggested a potential link between lipid-lowering therapies and neurocognitive effects, raising concerns regarding the possible adverse impact of PCSK9 inhibitors on memory loss.
Xuezhong Shi, Shijia Wang, Yongli Yang, Xudong Xia, Jingwen Fan, Jingjing Wang, Nana Wang, Xiaocan Jia   +7 more
doaj   +2 more sources

PCSK9 Inhibitors: The Evolving Future [PDF]

Health Science Reports
Introduction PCSK9 inhibitors are a novel class of medications that lower LDL cholesterol (LDL‐C) by increasing LDL receptor activity, promoting clearance of LDL‐C from the bloodstream.
Bijay Mukesh Jeswani, Shubhangi Sharma, Sawai Singh Rathore, Abubakar Nazir, Rohit Bhatheja, Kapil Kapoor   +5 more
doaj   +2 more sources

Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis [PDF]

International Journal of Cardiology. Cardiovascular Risk and Prevention
Background: Peripheral artery disease (PAD) reflects systemic atherosclerosis driven by dyslipidemia, particularly elevated LDL-C. Despite first-line statin therapy, many patients fail to reach lipid targets or are intolerant, necessitating alternatives.
Khadeeja Ali Hamzah, Yousif Hameed Kurmasha, Mohamed Fouad Abdrabo, Mohamed F. Srour, Ali Saad Al-Shammari, Mohammed Hamed Ibrahium Badi, Mohammedsadeq A. Shweliya, Nihar Jena, Yasar Sattar   +8 more
doaj   +2 more sources

PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis [PDF]

BMC Musculoskeletal Disorders
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent an effective strategy for reducing cardiovascular disease risk. Yet, PCSK9’s impact on osteoporosis remains unclear.
Ding-Qiang Chen, Wen-Bin Xu, Ke-Yi Xiao, Zhi-Qiang Que, Jin-Yi Feng, Nai-Kun Sun, Di-Xin Cai, Gang Rui   +7 more
doaj   +2 more sources

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression [PDF]

Pharmaceuticals
This paper investigates the therapeutic use of PCSK9 inhibitors, particularly Evolocumab, as monoclonal antibodies for the treatment of atherosclerosis based on recent literature reviews.
Maram H. Abduljabbar
doaj   +2 more sources

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation

Frontiers in Cardiovascular Medicine, 2023
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new cholesterol-lowering strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting PCSK9 and reducing the degradation of LDL receptors; thus, they are ...
Hongzhen Chen, Xiaomin Chen
doaj   +1 more source

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance

Безопасность и риск фармакотерапии, 2023
Scientific relevance. The main cause of cardiovascular pathologies is atherosclerosis, which is secondary to lipid metabolism disorders, in particular, the accumulation of low-density lipoprotein (LDL) cholesterol.
K. O. Shnaider, M. L. Maximov, V. A. Baranova, A. A. Nekipelova   +3 more
doaj   +1 more source

A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022

Frontiers in Endocrinology, 2023
BackgroundSince the approval of the proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies for marketing in 2015, PCSK9 inhibitors have attracted significant interest in the field of cardiovascular endocrinology.
Qin Luo, Qin Luo, Zhenchu Tang, Zhenchu Tang, Panyun Wu, Panyun Wu, Zhangling Chen, Zhangling Chen, Zhenfei Fang, Zhenfei Fang, Fei Luo, Fei Luo   +11 more
doaj   +1 more source

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System

Cardiovascular Therapeutics, 2022
Background. Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). Objective.
Lingqing Ding, Congqin Chen, Yongkuan Yang, Jie Fang, Longxing Cao, Yige Liu   +5 more
doaj   +1 more source

Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center

Journal of the Formosan Medical Association, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, are currently approved for clinical use by Taiwan National Health Insurance (NHI) in patients who had a recent atherosclerotic cardiovascular disease with ...
Chia-Ling Tsai, Ya-Hui Chang, Cheng-Huang Su, Yih-Jer Wu, Hung-I Yeh, Chao-Feng Lin   +5 more
doaj   +1 more source